A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This multi-center observational prospective study will collect real-world clinical and patient-reported outcome data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens or patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+, ISH-) breast cancer who have received at least a prior systemic therapy in the metastatic setting, or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat.
- •Potwierdzony nowotwór piersi, który nie może być operacyjnie usunięty lub ma przerzuty.
- •Grupa A: Potwierdzony wysoki poziom białka HER2 i co najmniej jedno poprzednie leczenie skierowane na HER2; nie więcej niż 2 linie terapii przy przerzutach.
- •Grupa B: Potwierdzony niski poziom białka HER2 i co najmniej jedno poprzednie leczenie systemowe przy przerzutach lub nawrót choroby podczas lub w ciągu 6 miesięcy po chemioterapii wspomagającej; nie więcej niż 2 wcześniejsze linie chemioterapii przy przerzutach.
- •Rozpoczęcie leczenia T-DXd lub pierwsza dawka podana nie więcej niż 14 dni przed włączeniem do badania.
- •Zdolność do wyrażenia świadomej zgody.
- •Preferowany jest udział pacjentów zdolnych do wypełniania kwestionariuszy; osoby niezdolne są zwolnione z wypełniania kwestionariuszy ale mogą uczestniczyć w badaniu.
✗ Disqualifies
- •Ciąża lub karmienie piersią.
- •Uczestnictwo w innym badaniu klinicznym, które jest lub pozostaje zaślepione.
- •Znana nadwrażliwość na substancję czynną T-DXd lub jej składniki.
- •Ocena lekarza, że pacjent nie jest zdolny do uczestnictwa w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (54)
China-Japan Friendship Hospital
Beijing, China
Peking University First Hospital
Beijing, China
The Fifth Medical Center of the Chinese PLA General Hospital
Beijing, China
Peking University Shougang Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing GoBroad Hospital
Beijing, China
Sichuan Cancer Hospital
Chengdu, China
Sichuan Provincial People's Hospital
Chengdu, China
Affiliated Zhongshan Hospital of Dalian University
Dalian, China
The First People's Hospital of Foshan
Foshan, China
Fujian Cancer Hospital
Fuzhou, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Hainan Cancer Hospital
Haikou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Anhui Provincial Cancer Hospital
Hefei, China
Jiamusi Cancer Hospital
Jiamusi, China
Yunnan Cancer Hospital
Kunming, China
The First People's Hospital of Lianyungang
Lianyungang, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, China
Jiangxi Cancer Hospital
Nanchang, China
Nanchang Third Hospital
Nanchang, China
Nanjing Drum Tower Hospital
Nanjing, China
Jiangsu Province Hospital
Nanjing, China
The Peoples of Guangxi Zhuang Autonomous Region
Nanning, China
Affiliated Hospital Of Nantong University
Nantong, China
Ningbo No.2 Hospital
Ningbo, China
Qingdao Central Hospital
Qingdao, China
Fudan University Shanghai Cancer Center
Shanghai, China
Changhai Hospital
Shanghai, China
Cancer Hospital of Shantou University Medical College
Shantou, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The University of Hong Kong- Shenzhen Hospital
Shenzhen, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
Tangshan People's Hospital
Tangshan, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, China
Weifang People's Hospital
Weifang, China
Wenzhou Central Hospital
Wenzhou, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Xi'an International Medical Center Hospital
Xi'an, China
The First Affilital of Xiamen University
Xiamen, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
General Hospital of Ningxia Medical University
Yinchuan, China
Henan Cancer Hospital
Zengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Henan Provincial People's Hospital
Zhengzhou, China
Zhongshan City People's Hospital
Zhongshan, China
The Fifth Affiliated Hospital, Sun Yat-sen University
Zhuhai, China
Trial contact
Daiichi Sankyo China
Daiichi Sankyo Contact for Clinical Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.